Jefferson P Lomenick1, Maciej S Buchowski2, Ashley H Shoemaker1. 1. Division of Pediatric Endocrinology, Vanderbilt University, Nashville, Tennessee, USA. 2. School of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
Abstract
OBJECTIVE: Hypothalamic obesity (HO) is a common complication of hypothalamic tumors, and effective therapies are lacking. The objective of this pilot study was to investigate changes in body weight before and during treatment with exenatide. METHODS: This was a prospective, open-label, 52-week pilot study of exenatide (10 mcg b.i.d.) in adults with HO. Ten patients enrolled, and eight completed the study. Study measures included indirect calorimetry, body composition, buffet meals, diet recall, actigraphy, and hormone assays. RESULTS: Participants had obesity with a baseline weight of 137.2 ± 37.6 kg. Exenatide therapy was well tolerated. Change in weight with exenatide therapy was not significant (-1.4 ± 4.3 kg [95% CI -4.9 to 2.2], P = 0.40), but six out of eight completers lost weight (-6.2 to -0.2 kg). Participants reported significantly lower intake on food recall during treatment compared with baseline (7837.8 ± 2796.6 vs. 6258.4 ± 1970.7 kJ [95% CI -2915.8 to -242.6], P = 0.027), but there was no change in intake during buffet meals. CONCLUSIONS: Significant weight loss was not observed in patients with HO treated with exenatide, but 75% of completers had stable or decreasing weight. Further studies are needed to evaluate weight loss efficacy in patients with HO.
OBJECTIVE:Hypothalamic obesity (HO) is a common complication of hypothalamic tumors, and effective therapies are lacking. The objective of this pilot study was to investigate changes in body weight before and during treatment with exenatide. METHODS: This was a prospective, open-label, 52-week pilot study of exenatide (10 mcg b.i.d.) in adults with HO. Ten patients enrolled, and eight completed the study. Study measures included indirect calorimetry, body composition, buffet meals, diet recall, actigraphy, and hormone assays. RESULTS:Participants had obesity with a baseline weight of 137.2 ± 37.6 kg. Exenatide therapy was well tolerated. Change in weight with exenatide therapy was not significant (-1.4 ± 4.3 kg [95% CI -4.9 to 2.2], P = 0.40), but six out of eight completers lost weight (-6.2 to -0.2 kg). Participants reported significantly lower intake on food recall during treatment compared with baseline (7837.8 ± 2796.6 vs. 6258.4 ± 1970.7 kJ [95% CI -2915.8 to -242.6], P = 0.027), but there was no change in intake during buffet meals. CONCLUSIONS: Significant weight loss was not observed in patients with HO treated with exenatide, but 75% of completers had stable or decreasing weight. Further studies are needed to evaluate weight loss efficacy in patients with HO.
Authors: L Blonde; E J Klein; J Han; B Zhang; S M Mac; T H Poon; K L Taylor; M E Trautmann; D D Kim; D M Kendall Journal: Diabetes Obes Metab Date: 2006-07 Impact factor: 6.577
Authors: H L Müller; K Bueb; U Bartels; C Roth; K Harz; N Graf; R Korinthenberg; M Bettendorf; J Kühl; P Gutjahr; N Sörensen; G Calaminus Journal: Klin Padiatr Date: 2001 Jul-Aug Impact factor: 1.349
Authors: Daniel Beiroa; Monica Imbernon; Rosalía Gallego; Ana Senra; Daniel Herranz; Francesc Villarroya; Manuel Serrano; Johan Fernø; Javier Salvador; Javier Escalada; Carlos Dieguez; Miguel Lopez; Gema Frühbeck; Ruben Nogueiras Journal: Diabetes Date: 2014-06-10 Impact factor: 9.461
Authors: Hermann L Müller; Maithé Tauber; Elizabeth A Lawson; Jale Özyurt; Brigitte Bison; Juan-Pedro Martinez-Barbera; Stephanie Puget; Thomas E Merchant; Hanneke M van Santen Journal: Nat Rev Dis Primers Date: 2022-04-21 Impact factor: 52.329
Authors: Jiska van Schaik; Dominique G A Begijn; Laura van Iersel; Yvonne Vergeer; Eelco W Hoving; Babette Peeters; Hanneke M van Santen Journal: Obes Facts Date: 2020-08-11 Impact factor: 3.942
Authors: Gitanjali Srivastava; Claudia K Fox; Aaron S Kelly; Ania M Jastreboff; Allen F Browne; Nancy T Browne; Janey S A Pratt; Christopher Bolling; Marc P Michalsky; Stephen Cook; Carine M Lenders; Caroline M Apovian Journal: Obesity (Silver Spring) Date: 2019-02 Impact factor: 5.002
Authors: Christian L Roth; M Jennifer Abuzzahab; Ashley H Shoemaker; Heidi J Silver; Maciej Buchowski; James C Slaughter; Jack A Yanovski; Clinton Elfers Journal: Int J Obes (Lond) Date: 2022-01-03 Impact factor: 5.551
Authors: Christian L Roth; Francisco A Perez; Kathryn B Whitlock; Clinton Elfers; Jack A Yanovski; Ashley H Shoemaker; M Jennifer Abuzzahab Journal: Diabetes Obes Metab Date: 2020-10-25 Impact factor: 6.577
Authors: Selveta S van Santen; Peter Wolf; Natalia Kremenevski; Cesar L Boguszewski; Hannes Beiglböck; Marta Fiocco; Mark Wijnen; Ville R Wallenius; Marry M van den Heuvel-Eibrink; Aart J van der Lely; Gudmundur Johannsson; Anton Luger; Michael Krebs; Michael Buchfelder; Patric J D Delhanty; Sebastian J C M M Neggers; Daniel S Olsson Journal: J Clin Endocrinol Metab Date: 2021-10-21 Impact factor: 5.958